Clarus Therapeutics Inc. announced positive results of an open-label, multi-center safety and efficacy analysis following two years of Jatenzo (testosterone undecanoate) oral capsules use in hypogonadal men.
Antares Pharma announced that the FDA has accepted its New Drug Application resubmission for Tlando (testosterone undecanoate), an oral treatment for testosterone replacement therapy.